DelveInsight's "Social Anxiety Disorder (SAD) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Social Anxiety Disorder Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Social Anxiety Disorder market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Social Anxiety Disorder: An Overview
Social Anxiety disorder (SAD), also called Social Phobia, is the most common mental health condition which causes extreme fear in social settings and an intense, persistent fear of being watched and judged by others. People with social anxiety disorder have trouble talking to people, meeting new people, attend social gatherings, which can also affect day-to-day activities.
Social anxiety is different from shyness which is usually short-term and doesn’t disrupt one’s life. Social anxiety is persistent and debilitating. It can affect one’s ability to work, attend school, and develop close relationships with people outside of their family.
Social Anxiety Disorder Market Key Facts
-
According to the National Institute of Mental Health (NIMH), about 1 in 8 people (12.1%) experience Social Anxiety Disorder at some time in their life and in a given year. According to the U.S. National Institutes of Health (NIH), SAD is the third most common psychiatric condition after depression and substance abuse. Of adults with social anxiety disorder in the past year, an estimated 29.9% had serious impairment.
-
According to Cambridge University (2020), epidemiologic surveys conducted across Europe indicated that the lifetime prevalence of Social anxiety disorder in the general population is close to 7%.
-
According to the National Institute of Health and Care Excellence (NICE), the lifetime prevalence of Social Anxiety disorder is 12% in the UK population.
-
As per Judith et al. (2017), the lifetime prevalence of Social Anxiety Disorder in Germany is found to be around 12%.
-
According to the analysis, females are more frequently diagnosed with SAD than males.
Social Anxiety Disorder Market
As per DelveInsight, the Social Anxiety Disorder market size is anticipated to increase in the coming years owing to the growth in R&D activity, increasing prevalent population, and expected commercial success of upcoming therapies in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Social Anxiety Disorder market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Social Anxiety Disorder market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Social Anxiety Disorder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Social Anxiety Disorder Epidemiology Segmentation
-
Total Prevalent Cases of Social Anxiety Disorder
-
Age-specific Prevalence of Social Anxiety Disorder
-
Severity-specific cases of Social Anxiety Disorder
-
Gender-specific Prevalence of Social Anxiety Disorder
-
Total diagnosed cases of Social Anxiety Disorder
-
Total treated cases of Social Anxiety Disorder
Social Anxiety Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Social Anxiety Disorder market or expected to get launched during the study period. The analysis covers the Social Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Social Anxiety Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Social Anxiety Disorder Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/social-anxiety-disorder-market
Key Developments in the Social Anxiety Disorder Therapeutics Market
On September 08, 2022, Vistagen Therapeutics (Nasdaq: VTGN) announced the completion of an interim analysis of PALISADE-2, the Company’s second Phase 3 clinical trial assessing drug candidate PH94B as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD).
Some of the key companies in the Social Anxiety Disorder Market include:
-
Bionomics
-
Vistagen Therapeutics
-
Vanda Pharmaceuticals
And many others
Social Anxiety Disorder Therapies covered in the report include:
-
PH94B
-
VQW-765
-
BNC210
And many more
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More -
https://www.delveinsight.com/sample-request/social-anxiety-disorder-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Social Anxiety Disorder Competitive Intelligence Analysis
4. Social Anxiety Disorder Market Overview at a Glance
5. Social Anxiety Disorder Disease Background and Overview
6. Social Anxiety Disorder Patient Journey
7. Social Anxiety Disorder Epidemiology and Patient Population (In US, EU5, and Japan)
8. Social Anxiety Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Social Anxiety Disorder Unmet Needs
10. Key Endpoints of Social Anxiety Disorder Treatment
11. Social Anxiety Disorder Marketed Products
12. Social Anxiety Disorder Emerging Drugs and Latest Therapeutic Advances
13. Social Anxiety Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Social Anxiety Disorder Market Outlook (In US, EU5, and Japan)
16. Social Anxiety Disorder Access and Reimbursement Overview
17. KOL Views on the Social Anxiety Disorder Market
18. Social Anxiety Disorder Market Drivers
19. Social Anxiety Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/social-anxiety-disorder-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Neuroleptic Malignant Syndrome Market
“Neuroleptic Malignant Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Neuroleptic Malignant Syndrome Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
